Crossmark

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern

Crossref DOI link: https://doi.org/10.1038/s41467-023-38457-x

Published Online: 2023-05-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Komori, Mai https://orcid.org/0000-0001-8999-3456
Nogimori, Takuto https://orcid.org/0000-0002-6011-9631
Morey, Amber L. https://orcid.org/0000-0003-3401-9853
Sekida, Takashi

Ishimoto, Keiko https://orcid.org/0000-0002-9188-6702
Hassett, Matthew R.

Masuta, Yuji https://orcid.org/0000-0003-2349-6320
Ode, Hirotaka

Tamura, Tomokazu https://orcid.org/0000-0003-1395-6610
Suzuki, Rigel

Alexander, Jeff

Kido, Yasutoshi https://orcid.org/0000-0003-3615-2631
Matsuda, Kenta

Fukuhara, Takasuke https://orcid.org/0000-0001-5471-8331
Iwatani, Yasumasa https://orcid.org/0000-0001-9269-4828
Yamamoto, Takuya https://orcid.org/0000-0003-3753-1211
Smith, Jonathan F. https://orcid.org/0000-0002-8069-2128
Akahata, Wataru https://orcid.org/0000-0001-9207-6923
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)

Japan Agency for Medical Research and Development (JP21nf0101627)
License Information

Text and Data Mining valid from 2023-05-19

Version of Record valid from 2023-05-19
More Information

Article History

Received: 26 October 2022

Accepted: 27 April 2023

First Online: 19 May 2023

Competing interests

: M.K., A.L.M., K.I. and K.M. are employees (VLP Therapeutics, Inc.); W.A. is a board member, an employee and holds stocks (VLP Therapeutics, Inc.); J.F.S. is an employee and holds stocks (VLP Therapeutics. Inc.); J.A. and M.R.H. were employees at VLP Therapeutics. T.S. is an employee (VLP Therapeutics Japan, LLC); W.A. is a management board member (VLP Therapeutics Japan, LLC); W.A. and J.F.S. are inventors on related vaccine patents (Coronavirus vaccine #17/232666 and Efficient vaccine #18/067358). The remaining authors declare no competing interest.

Document is current

Any future updates will be listed below